Skip to main content
. 2021 Dec 9;7(1):100342. doi: 10.1016/j.esmoop.2021.100342

Figure 2.

Figure 2

Progression-free survival and central nervous system (CNS) progression-free survival of patients treated with alectinib plus bevacizumab.

Kaplan–Meier curves depicting (A) progression-free survival and (B) CNS progression-free survival of 11 patients enrolled in the study.

CI, confidence interval; NR, not reached; PFS, progression-free survival.